Objective-Platelets, which are mainly known for their role in hemostasis, are now known to play a crucial role in metastasis.
T he role of platelets in malignancy is emerging as an important and attractive area of investigation. It has now been demonstrated that platelets are essential to all stages of primary tumor growth, as well as metastatic spread. 1 Platelets aid disseminating tumor cells by protecting them from high shear forces and immune surveillance within the circulation, forming tumor cell-platelet aggregates that facilitate embolization, promoting adhesion of tumor cells to the vascular endothelium, and releasing a variety of soluble factors that promote tumor growth, metastasis, and angiogenesis. 2 Platelets carry a plethora of angiogenic factors within their α-granules, including the potent proangiogenic protein vascular endothelial growth factor (VEGF). 3, 4 In fact, platelets seem to be the main storage site for angiogenic proteins; 80% of circulating VEGF is stored in platelet α-granules. 5 Previously, our group and others have demonstrated that platelets differentially release pro-and antiangiogenic factors, such as VEGF and endostatin in an agonist-dependent manner. [5] [6] [7] [8] Platelets are also activated on exposure to breast tumor cells, and this leads to the release of potent proangiogenic mediators. 6 In breast cancer in particular, angiogenesis is key to tumor growth and metastasis, including ductal carcinoma in situ. 9 Overexpression of angiogenic factors, such as VEGF, in breast tumor tissue is associated with poor clinical outcome and lower response to chemotherapeutic and hormonal-based treatment regimens. 10, 11 In addition, VEGF levels in serum have been deemed an independent prognostic factor for survival, and there is a correlation between platelet levels of VEGF and disease progression. 12, 13 Recently, we have demonstrated that intervention with aspirin and anticoagulant drugs can significantly diminish the release of granule components from platelets. As such, the angiogenic potential of aspirin-treated platelets is inhibited in response to breast cancer tumor cells.
Tamoxifen is a selective estrogen receptor modulator that is used widely as antiestrogen therapy for breast cancer. Tamoxifen treatment is associated with a 50% reduction in the risk of invasive and noninvasive breast cancer in women who used the drug for at least 5 years. 15 Interestingly, tamoxifen has demonstrated anticancer efficacy in estrogennegative cancers, suggesting that this drug has additional mechanisms of action. 16 Platelets express ER-α and ER-β (the receptors for estrogen), and a role for estrogen in platelet function has been investigated previously. 17, 18 Some studies have suggested that tamoxifen may stimulate platelet aggregation in vitro and in vivo 19, 20 ; however, more recent data support an inhibitory role in platelet activation. 21, 22 Mechanistically, Chang et al 21 have recently demonstrated that tamoxifen inhibits platelet activation through the inhibition of PLC-2-PKC-p38 signaling. Although the impact of tamoxifen on platelets has been examined in the context of cardiovascular disease, to date no studies have investigated the effect of platelet inhibition by tamoxifen on breast cancer angiogenesis or metastasis.
In this article, we aim to demonstrate that tamoxifen and its metabolites significantly diminish the release of platelet angiogenic factors and metastatic factors, leading to decreased tumor cell support. The mechanism is directly linked to the inhibitory role of tamoxifen in platelet activation, causing altered release of key angiogenic and metastatic factors during tumor cell and platelet crosstalk.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
Patients on tamoxifen therapy release less VEGF and have diminished platelet angiogenic potential.
Previous work from our group has shown that drugs that inhibit platelet function, such as aspirin and anticoagulants, 6, 14 can disrupt proangiogenic platelet-tumor cell crosstalk. Recent in vitro studies have shown that tamoxifen can directly alter platelet function; therefore, we hypothesized that tamoxifen therapy may augment the proangiogenic response of platelets to tumor cells. 21, 22 We conducted translational studies using blood samples collected from patients with breast cancer on tamoxifen therapy to determine whether systemic, therapeutic levels of tamoxifen impacted platelet-mediated angiogenesis. Patients receiving adjuvant tamoxifen therapy for breast cancer for at least 1 month and who were not taking any additional platelet inhibiting drugs were selected for this study. Platelets were isolated from patients or healthy controls and activated ex vivo by a 10-minute exposure to MCF-7 breast tumor cells to generate an activated platelet releasate ( Figure 1A, schematic) . Previously, we showed that platelets release proangiogenic VEGF in response to tumor cells. 6 We measured VEGF in releasate collected from activated platelets and found that platelets from patients receiving tamoxifen release significantly less VEGF on activation by MCF-7 tumor cells ( Figure 1C ). To determine whether tamoxifen therapy leads to a net decrease in angiogenic potential, we used these platelet releasates in capillary tube formation assays. Capillary tube formation was significantly lower in patient samples compared with controls ( Figure 1D and 1E) , demonstrating that tamoxifen therapy inhibits the proangiogenic potential of platelets during platelet-tumor cell cross talk.
Tamoxifen Inhibits Tumor CellInduced Platelet Activation
To determine whether the decrease in VEGF release and angiogenic potential were the result of impaired platelet activation in response to tumor cells, surface expression of the platelet activation marker P-selectin was measured using flow cytometry. We have previously shown that MCF-7 breast tumor cells induce platelet activation. 6 We confirmed that P-selectin increased 2.3-fold in MCF-7-activated platelets from healthy donors ( Figure 1B ). However, platelets from patients taking tamoxifen displayed significantly diminished activation response ( Figure 1B ), indicating that therapeutic levels of tamoxifen cause inhibition of platelet activation in response to breast tumor cells.
To further examine the effect of tamoxifen on platelet activation, platelets from healthy human donors were pretreated ex vivo with tamoxifen or vehicle control (Figure 2A , schematic), washed, and then stimulated with various agonists: ADP, MCF-7 breast tumor cells, or thrombin receptor-activating peptide (TRAP). Doses of 10 to 20 μmol/L tamoxifen were selected based on previously reported studies. [21] [22] [23] ADP, MCF-7 cells, and TRAP all significantly increased P-selectin surface expression compared with resting platelets ( Figure 2B and 2C). However, pretreatment of platelets with tamoxifen caused a dose-dependent decrease in ADP-induced activation ( Figure 2D ). Tamoxifen did not alter activation in response to the strong agonist TRAP at either concentration examined. Importantly, pretreatment of platelets with tamoxifen significantly reduced MCF-7-induced activation. Tamoxifen treatment alone had no effect on P-selectin expression in resting platelets ( Figure 2C ). Representative histograms showing P-selectin expression are depicted in Figure 2B . These results confirm that tamoxifen directly and dose-dependently inhibits tumor cell-induced platelet activation, disrupting platelettumor cell crosstalk.
Tamoxifen Directly Inhibits Angiogenic Potential of Tumor Cell-Activated Platelets
Next, we sought to further examine the effect of tamoxifen on the angiogenic potential of tumor cell-activated platelets that we observed in our patient cohort. We pretreated platelets with tamoxifen before activation by MCF-7 cells and measured the release of VEGF ( Figure 3A , schematic). Activation with MCF-7 cells increased the release of proangiogenic VEGF, whereas tamoxifen pretreatment reduced VEGF release to baseline levels ( Figure 3B ). Next, we sought to determine whether tamoxifen could directly alter the net angiogenic effect of platelets. We have previously shown that releasate from platelets activated by MCF-7 cells increases endothelial cell migration and capillary tube formation. 6 Here, we pretreated platelets with tamoxifen (10 or 20 μmol/L) before activation with MCF-7 cells and tested the angiogenic potential of the resulting releasate using functional angiogenesis assays ( Figure 3A , schematic). We also tested the angiogenic potential of these releasates in capillary tube formation assays. MCF-7-activated platelet releasate induced increased capillary tube formation compared with releasate from resting, unactivated (resting) platelets ( Figure 3C and 3D).
Releasates from platelets pretreated with tamoxifen before activation induced significantly less capillary tube formation after 6 hours compared with controls ( Figure 3D ). Endothelial migration, a critical step in angiogenesis, was sharply and significantly increased in response to releasate from MCF-7-activated platelets ( Figure 3E and 3F). However, no significant increase in endothelial cell migration was observed when platelets were treated with tamoxifen before MCF-7 activation ( Figure 3E and 3F) . These results suggest that tamoxifen lowers the net angiogenic potential of platelets and that this may be one of the ways by which tamoxifen works to control tumor growth.
Tamoxifen Decreases the Metastatic Potential of Platelets
Because platelets are also known to have prometastatic effects in breast cancer, [24] [25] [26] we next examined the effect of tamoxifen on platelet-mediated metastasis. To test this, we examined the effect of tamoxifen on the metastatic potential of platelets using standard in vitro metastasis assays: tumor cell invasion and transendothelial migration. For invasion assays, human platelets were pretreated with 20 μmol/L tamoxifen or dimethyl sulfoxide vehicle control, washed, and activated with MCF-7 tumor cells to generate a releasate. We measured the effect of these releasates on MCF-7 tumor cell invasion through matrigel and found that activated platelet releasate increased MCF-7 invasion compared with resting releasate (Figure 4A and 4B). Pretreatment with tamoxifen diminished the ability of activated releastes to promote MCF-7 invasion by 76% ( Figure 4A and 4B). Transendothelial migration, or the ability of tumor cells to cross an endothelial barrier, is a critical step in the metastatic process. Platelets can aid tumor cells in this process, as demonstrated by the ability of live platelets to increase the migration of MCF-7 tumor cells across an endothelialized membrane by 2.6-fold over platelet-free control ( Figure 4C ). In contrast, tamoxifen pretreatment completely prevented platelets from promoting the transendothelial migration of tumor cells ( Figure 4C ). Platelets were isolated from patients on tamoxifen maintenance therapy or healthy controls and activated by exposure to MCF-7 breast tumor cells for 10 minutes to generate an activated platelet releasate (A). Activation was determined by P-selectin surface expression using flow cytometry after activation with MCF-7 tumor cells (B). Vascular endothelial growth factor (VEGF) release from platelets was measured in resulting releastes by ELISA (C). MCF-7 activated or resting platelet releasates from patients were used in capillary tubes assays and compared with releasates from healthy controls. Representative images are shown (D), and results from all replicates are quantified (E). Bars indicate SEM. *P<0.05 by ANOVA, n=3 to 6 independent replicates per treatment group. Scale bars represent 100 µm.
Tamoxifen Metabolite 4-OH Inhibits Platelet Activation and VEGF Release
Tamoxifen is a prodrug and is metabolized into more active forms in the body. 27 Therefore, we hypothesized that a metabolite may contribute to the dramatic results seen in patient samples (Figure 1 ). 4-Hydroxytamoxifen (4-OH), a tamoxifen metabolite found in the blood, 27, 28 has been shown to inhibit platelets activation and aggregation. 22 Therefore, we tested whether 4-OH could also inhibit platelet-mediated angiogenesis and metastasis. Platelets from healthy human donors were pretreated with 25 or 50 μmol/L of 4-OH or vehicle control, washed to remove the drug, and then activated by various agonists. Unlike tamoxifen, 4-OH significantly and dose dependently inhibited platelet activation in response to the strong agonist TRAP ( Figure 5A ). 4-OH also lowered activation in response to MCF-7 tumor cells; however, this reduction did not reach statistical significance ( Figure 5A ). More significant inhibition was, however, achieved in response to the aggressive, triple negative breast cancer cell line MDA-MB-231. VEGF release also trended toward a reduction with 4-OH ( Figure 5B ), prompting us to look for other angiogenic factors through angiogenic protein array studies as shown in Figure 5C through 5E. The robust response, particularly against the strong agonist TRAP and the aggressive MDA-231 cells, suggests that the 4-OH metabolite of tamoxifen has potent effects on platelets. Therefore, we further characterized the effect of 4-OH on platelet-mediated angiogenesis and metastasis.
Tamoxifen Metabolite 4-OH Dampens Release of Proangiogenic and Metastatic Factors
To further characterize how 4-OH alters the release of platelet factors, we performed a membrane-based array (C1000; RayBiotech) to simultaneously detect 43 proteins known to be involved in angiogenesis and cancer. Releasates generated from MCF-7 or TRAP-activated platelets after treatment with 50 μmol/L 4-OH or vehicle control were compared by membrane-based array. Proteins that showed a 1.5-fold or greater change in response to tamoxifen or 4-OH are reported ( Figure 5C through 5E). We found that 4-OH inhibited the release of key regulators of angiogenesis and metastasis, including angiogenin, CCL5 (RANTES), CXCL1, EGF, MMP-1, PDGF, and TGFβ ( Figure 5C ). A complete list of proteins found to be altered by 4-OH is depicted in Figure 5E . For MCF-7-activated platelets, a similar effect was observed ( Figure 5D ). 4-OH also inhibited the release of CXCL1, CCL5, EGF, CXCL5, and PDGF from MCF-7-activated platelets ( Figure 5C ). Interestingly, 4-OH increased the release of angiopoietin-1, a protein known to inhibit tumor angiogenesis, in response to MCF-7 cells ( Figure 5C ). Results are summarized in Figure 5E . Overall, these array date indicate that 4-OH can alter the release of factors from platelets in ways that could limit the proangiogenic and metastatic role of platelets in breast cancer.
Tamoxifen Metabolite 4-OH Decreases Platelet Angiogenic and Metastatic Potential
The tamoxifen metabolite 4-OH caused potent inhibition of activation and protein release above and beyond what we observed with tamoxifen. Therefore, we next examined the impact of 4-OH on the net angiogenic and metastatic effects of platelets. Platelets were pretreated with 4-OH, washed, and activated with tumor cells or TRAP to generate releasates. Both TRAP and tumor cell-activated platelet releasates significantly increased capillary tube formation over releasate from resting platelets ( Figure 6A and 6B) . Similar to what we observed with tamoxifen, 4-OH pretreatment abolished the increase in capillary tube formation caused by activated platelet releasate ( Figure 6A and 6B) . Metastatic potential was also diminished by 4-OH; activated platelet releasates promoted the invasion of MCF-7 tumor cells through matrigel, whereas 4-OH pretreatment abrogated this effect, returning invasion to baseline ( Figure 6C and 6D) .
Overall, our work suggests that tamoxifen and its 4-OH metabolite directly alter platelet function, leading to dampened activation responses and an alteration in angiogenic and metastatic protein release. The net effect leads to platelets that have significantly reduced angiogenic and metastatic effects in response to breast tumor cells (Figure 6E, model) . Translational studies using platelets isolated from patients undergoing adjuvant tamoxifen therapy confirm that therapeutic, systemic tamoxifen use leads to platelet inhibition and lower net angiogenic potential.
Discussion
Previous studies have shown that tamoxifen can directly alter platelet function and that tamoxifen use may impact the role of platelets in thrombosis and cardiovascular disease. 19, [21] [22] [23] Although platelets have a well-established role in cancer progression and metastasis to date, this study is the first to examine the effect of tamoxifen on platelet function in the context of breast cancer, the disease for which tamoxifen is most widely used. Overall, our studies reveal that tamoxifen directly inhibits tumor cell-induced platelet activation and substantially dampens the proangiogenic and prometastatic effects of platelets.
The existing body of literature on the effect of tamoxifen on platelets is somewhat contradictory, with a few studies showing platelet activation or aggregation in response to tamoxifen.
19 Figure 4 . Tamoxifen decreases the metastatic potential of platelets. To determine the metastatic potential of tamoxifen-treated platelets, releasates were generated as described in Figure 3A and used in standard transwell invasion assays. The ability of MCF-7 tumor cells to invade through Matrigel in response to platelet releasates was quantified (A) and representative images are shown (B). Transendothelial migration assays were performed in which MCF-7 tumor cells cross an endothelialized transwell membrane in the presence or absence of live platelets pretreated with 0 or 20 μmol/L tamoxifen (C). Bars indicate SEM. *P<0.05, **P<0.01 by ANOVA, n=3 to 5 independent replicates per treatment group. Scale bars represent 100 µm.
However, the majority of recent studies report inhibition of platelet activation 21, 22 ; the discrepancy between studies could be because of doses, agonists used, or aspect of platelet function analyzed. Serum levels of tamoxifen and its metabolites have been reported to be highly variable, with up to a 10-fold difference detected among patients on comparable doses. 29, 30 Interestingly, Kisanga et al 31 reported that breast tumor tissue contains significantly higher concentrations of tamoxifen Releasates from platelets treated with 50 μmol/L 4-hydroxytamoxifen (4-OH) or vehicle control were assayed for angiogenic potential using capillary tube formation assays. Capillary tube formation was quantified as the average number of branch points per field of view (B), with representative images shown (A). To determine the metastatic potential of 4-OH-treated platelets, releasates were generated as previously described and used in standard transwell invasion assays. The ability of MCF-7 tumor cells to invade through Matrigel in response to platelet releasates was quantified (C) and representative images are shown (D). Model: tamoxifen and its metabolites directly inhibit platelet activation in response to breast tumor cells, leading to a decreased release of tumor-supporting proangiogenic and prometastatic factors from platelets (E). Bars indicate SEM. **P<0.01, ***P<0.001 by ANOVA, n=3 independent replicates per treatment group. compared with serum. It is well established that platelets interact with tumor cells in both the blood and the tumor tissue and they may, therefore, encounter different doses of tamoxifen based on location. Although these findings make it challenging to directly compare in vitro and in vivo studies, we have demonstrated decreased activation and angiogenic potential in platelets treated with tamoxifen ex vivo and more importantly in platelets isolated from patients on tamoxifen therapy.
The exact mechanism by which tamoxifen and its metabolites impact function has not been fully elucidated, but some key studies provide insight. Platelets express estrogen receptors α and β, but it remains unclear whether tamoxifen exerts its effects on platelets through these receptors. 23 Of note, use of estrogen receptor blockers, such as ICI 182.780, do not reverse the effects of tamoxifen, suggesting that the effects of tamoxifen on platelet inhibition are not mediated directly through the estrogen receptor. 21, 22 Mechanistically, Chang et al 21 have demonstrated that tamoxifen inhibits the PKC pathway via PLCγ 2 as well as the p38 MAPK pathway in platelets. Interestingly, this group and others have shown that tamoxifen also causes a rise in platelet intracellular calcium, which would suggest a proactivation effect; however, abrogation of downstream pathways, such as PKC or cAMP production, could explain inhibition in the presence of elevated calcium. 21, 23 Our results are in line with the majority of studies, confirming that tamoxifen and 4-OH inhibit platelet activation. Furthermore, we went on to show that tamoxifen and 4-OH also specifically inhibit platelet activation in response to breast tumor cells.
In addition to inhibiting activation, tamoxifen altered the release of angiogenic mediators from platelets. We found that tamoxifen inhibited the release of VEGF. This finding is supported by the work of Holmes et al 5 who reported altered levels of VEGF in patients on tamoxifen therapy. Furthermore, our array results show that 4-OH inhibits the release of other proangiogenic factors, including angiogenin and PDGF. Our array results also detected elevated angiopoietin-1 in releasates from tamoxifen and 4-OH-treated platelets. Angiopoietin-1 is primarily involved in vessel stabilization and has a well-known antiangiogenic role in cancer. 32, 33 Overall, these changes could lead to a platelet releasate with enhanced antiangiogenic properties. Indeed, releasates from tamoxifen-treated platelets had a dramatically reduced net angiogenic potential in functional assays. Because angiogenesis is critical for breast cancer progression and platelets are a main source of angiogenic regulators, including VEGF, these results strongly suggest that tamoxifen may improve breast cancer outcomes by limiting the proangiogenic effects of platelets.
The importance of platelets in cancer progression and metastasis is now widely appreciated. 2 In this study, we found that tamoxifen pretreatment potently inhibited the ability of platelets to promote metastasis in vitro. Platelets support metastasis through direct, paracrine effects on tumor cells that have been shown to enhance tumor cell migration, invasion, and epithelial to mesenchymal transition. 2 Platelets also support metastasis by exerting effects on other cells in the tumor microenvironment, such as endothelial cells and cells of the immune system. 6, [34] [35] [36] Our array results identified decreased levels of CXCL1, CCL5, EGF, and CXCL5 in tumor cell-activated releasate from 4-OH-treated platelets. These proteins are all known to play a role in cancer progression and metastasis. [37] [38] [39] [40] [41] Future studies are needed to examine these factors individually in the context of tamoxifen and look at how tamoxifen reprograms platelets in ways that limit cancer progression.
Recently, interest in antiplatelet agents as cancer therapeutics has grown. GPIIb/IIIa blockers and the P2Y12 antagonist clopidogrel show antitumor and antimetastasis properties in vitro and in murine models of cancer. 42, 43 Anticoagulants, including low-molecular-weight heparins and fondaparinux, inhibit tumor cell-induced platelet activation and attenuate the angiogenic potential of platelets in vitro.
14 Aspirin is perhaps the most intriguing antiplatelet agent that has been studied to date, and several epidemiological studies have suggested that individuals who take aspirin daily are less likely to be diagnosed with cancer and show improved survival if they do develop cancer. 44 The randomized phase III ABC (Aspirin for Breast Cancer)Trial will prospectively study whether adjuvant aspirin can reduce the risk of breast cancer recurrence. Tamoxifen, a selective estrogen receptor modulator, is predominantly indicated for the treatment of hormone receptor-positive cancers; however, our findings build on a growing body of evidence, demonstrating that tamoxifen also has direct antiplatelet activity. This report highlights the need to examine the efficacy of tamoxifen in estrogen receptor-negative cancers as an antiplatelet agent and supports the exploration of antiplatelet agents as cancer fighting therapeutics.
